Translate page

  • Presentations from the EHA2022 Congress

  • EHA 2022: Mechanisms of disease progression in chronic myeloid leukemia (S. Tiong Ong)

  • EHA 2022: Non-BCR-ABL1 biomarkers of prognosis in CML (Shady Awad)

  • COLT Meeting 2019: CML related topics

  • COLT Meeting 2019: The CML frontier

    Highlights from EHA 2016:
    3 CML experts give their personal perspectives

    This independent educational resource is supported by a grant from Novartis Oncology

    Perspectives from Prof. Michele Baccarani
    Chairman of CML Working Party of European LeukemiaNet,
    Founding member of the iCMLf, Università di Bologa, Italy

    • The unmet needs in CML
    • Pathways to treatment free response
    • Next generation sequencing - the impact on future treatment decision making

     {rscomments off}